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Due to the lack of specificity for tumor antigens, allogeneic T-celltherapy is associated with graft-versus-host disease. Enhancingthe anti-tumor specificity while reducing the graft-versus-host
disease risk of allogeneic T cells has remained a research focus. In this
study, we demonstrate that the introduction of ‘dominant’ T-cell recep-
tors into primary murine T cells can suppress the expression of endoge-
nous T-cell receptors in a large proportion of the gene-modified T cells.
Adoptive transfer of allogeneic T cells expressing a ‘dominant’ T-cell
receptor significantly reduced the graft-versus-host toxicity in recipient
mice. Using two bone marrow transplant models, enhanced anti-tumor
activity was observed in the presence of reduced graft-versus-host dis-
ease. However, although transfer of T-cell receptor gene-modified allo-
geneic T cells resulted in the elimination of antigen-positive tumor cells
and improved the survival of treated mice, it was associated with accu-
mulation of T cells expressing endogenous T-cell receptors and the
development of delayed graft-versus-host disease. The in vivo deletion of
the engineered T cells, mediated by endogenous mouse mammary
tumor virus MTV8 and MTV9, abolished graft-versus-host disease while
retaining significant anti-tumor activity of adoptively transferred T cells.
Together, this study shows that the in vitro selection of allogeneic 
T cells expressing high levels of a ‘dominant’ T-cell receptor can lower
acute graft-versus-host disease and enhance anti-tumor activity of adop-
tive cell therapy, while the in vivo outgrowth of T cells expressing
endogenous T-cell receptors remains a risk factor for the delayed onset
of graft-versus-host disease.
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ABSTRACT
Introduction
TCR gene transfer is an attractive strategy to direct T-cell specificity towards
defined target antigens.1-6 This approach can readily produce large numbers of anti-
gen-specific T cells for adoptive cell therapy and no longer requires the selection
and expansion of rare specificities present in the autologous TCR repertoire. Recent
clinical trials have shown the feasibility and efficacy of TCR gene therapy in
melanoma and synovial cell carcinoma.7 However, the safety concerns of TCR gene
therapy include the mis-pairing of introduced TCR chains with the endogenous
chains expressed in the gene-modified T cells. Recent murine model experiments
have indicated that TCR mis-pairing can generate auto-reactive T cells that cause
toxicity when adoptively transferred into syngeneic hosts.8 It is likely that similar
toxicities can occur in humans, although it has not yet been described in clinical tri-
als to date.
One of the most effective forms of T-cell therapy in humans is the adoptive trans-
fer of allogeneic donor T cells into patients transplanted with hematopoietic stem
TCR transfer to suppress allo-reactivity
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cells derived from the same donor, typically as a T-cell
replete allogeneic hematopoietic stem cell transplantation
(HSCT) or post allo-HSCT donor lymphocyte infusion
(DLI).9 In this scenario, allo-reactive donor T cells can effi-
ciently attack and eliminate patient leukemia cells, result-
ing in cure of the malignant disease. However, since the
major and minor histocompatibility antigens recognized
by allo-reactive T cells are not selectively expressed in
leukemia cells, but also in normal tissues, this can lead to
normal tissue damage and result in graft-versus-host dis-
ease (GvHD).10 Thus, enhancing the leukemia specificity
while reducing the ‘damaging’ allo-reactive potential of
donor T-cell therapy has remained the focus of research. 
A recent study has demonstrated in a fully MHC-mis-
matched murine transplant model that TCR gene transfer
into donor T cells was able to enhance graft-versus-
leukemia (GvL) and reduce GvHD. In this study, Koestner
et al. transferred the OT1-TCR, specific for a peptide epi-
tope of ovalbumin, into donor T cells and achieved 
20%-70% reduction of the endogenous TCR repertoire.11
Here, we explored whether ‘dominant’ TCR can mediate
complete inhibition of endogenous TCR expression in
donor T cells in vivo. Together with other groups, we had
previously shown that ‘dominant’ TCR can suppress the
expression of ‘non-dominant’ TCR on the surface of gene-
modified T cells in vitro.12-14 The mechanism of TCR domi-
nance has not yet been fully defined, but it may involve
transcriptional and translational regulation as well as the
efficiency of the TCR α and β chain pairing and assembly
with CD3 chains prior to the migration of the TCR com-
plex from the endoplasmic reticulum to the cell surface.
The observation that modifications improving RNA trans-
lation into protein and modifications improving TCR α/β
chain pairing both enhanced TCR dominance indicated
that efficient protein synthesis and efficient formation of
α/β heterodimers have a direct impact on TCR domi-
nance.12 Here, we have codon optimized the TCR gene
sequences and introduced additional disulphide bonds in
the constant domains to generate ‘dominant’ TCR. We
tested the ability for these ‘dominant’ TCR constructs to
suppress the surface expression of endogenous TCR in
polyclonal primary T cells in vitro. We then performed 
in vivo experiments to test the working hypothesis that the
introduction of a ‘dominant’ TCR into allogeneic donor 
T cells may control graft-versus-host toxicity, while
enhancing protection against tumors expressing the target
antigen recognized by the ‘dominant’ TCR.
Methods
Mice
Female C57BL/6, C57BL/6 (Thy1.1), BALB/c, BALB/c (Thy1.1)
and DBA/J1 mice were purchased from Charles Rivers
Laboratories or bred in house by UCL Biological Services. All
experiments were conducted in accordance with United Kingdom
Home Office regulations. 
Cell lines, pentamer and peptide
Phoenix-Ecotropic (PhEco) adherent packaging cells (Nolan
Laboratory) were transiently transfected with retroviral vectors for
the generation of supernatant containing the recombinant retro-
virus required for infection of target cells. EL4 is a murine lym-
phoma cell line, EL4-NP a variant, stably expressing the influenza
A virus nucleoprotein (NP) (a kind gift from Dr B. Stockinger).  The
pentamer consisted of pNP366 bound to H2-Db. The influenza A
virus NP-derived peptide, pNP366 (ASNENMDAM) is presented
by H2-Db MHC Class-I molecules and was obtained from
Proimmune.
Vectors
The retroviral F5-TCR vector pMP71-TCRα-2A-TCRβ was
modified from pMX-TCRα-IRES-TCRβ (a kind gift from Prof T.
Schumacher). The F5-TCR recognizes the influenza A virus NP
(NP366-374) peptide in the context of murine H2-Db MHC Class-I. For
tumor challenge experiments, we either used the F5-TCR vector
or a version of it encoding for a truncated CD19 downstream of
an IRES sequence as a marker of transduction. CD19 staining was
used to track adoptively transferred DBA/J1 donor T cells, which
lacked a congenic marker. The retroviral OTII-TCR vector pMP71-
TCRα-2A-TCRβ was generated in the lab. The OTII-TCR recog-
nizes the OVA (OVA323-339-ISQAVHAAHAEINEAGR) peptide in
the context of murine H2-Ab MHC Class-II. The control vector
pMP71-iCre-IRES-GFP (inverted Cre-recombinase) was generated
in the lab. The retroviral pMP71 vectors containing the F5- or
OTII-TCR were modified for optimal gene (and surface TCR)
expression by codon optimization and addition of an engineered
cysteine bond between the TCR chains (Geneart).
Bone marrow transplantation, T-cell transfer and tumor
challenge
Recipient mice (Thy1.2) were lethally irradiated (C57BL/6, 11
Gy; BALB/c, 8 Gy X-ray irradiation split into 2 fractions, separated
by 24 h) and T-cell depleted bone marrow cells were injected intra-
venously 4 h later. Vβ11 or NP-pentamer sorted donor T cells
(Thy1.1) were adoptively transferred via the tail vein the following
day. Mock transduced T cells were used as control. On the same
day, mice received i.p. injections of C57BL/6 bone marrow derived
DCs pulsed with NP peptide. Five doses of 105U IL2 (Chiron) i.p.
were administered to recipient mice, with the first dose given on
the day of T-cell transfer and subsequently twice daily on the fol-
lowing two days. 
For tumor challenge experiments, C57BL/6 recipient mice
(Thy1.2) were conditioned as described above, but with the addi-
tion of subcutaneous inoculation of 106 EL4-NP cells on the day of
bone marrow transplantation. NP-pentamer sorted donor T cells,
either from DBA/J1 (Figure 4) or BALB/c (Figure 5) origin were
transduced with the F5-TCR and adoptively transferred via the tail
vein the following day. GFP sorted or mock transduced T cells
were used as a control. Tumors were measured with a calliper in
two different dimensions (a and b) at different intervals and the
growth evaluated applying the following formula: axbx /4.
Results
Dominant TCR can suppress expression of endogenous
TCR
In this study, we have used an MHC Class-I restricted
TCR (F5-TCR) specific for a peptide epitope of the
influenza virus nucleoprotein presented by H2-Db and an
MHC Class-II restricted TCR (OTII-TCR) specific for an
ovalbumin-derived peptide presented by H2-Ab. Both
TCR constructs were codon optimized and contained an
additional disulphide bond in the constant domain to
improve RNA translation and α/β chain pairing. The mod-
ified F5- and OTII-TCR genes were inserted into the retro-
viral pMP71 vector for gene transfer into primary murine
T cells. In order to test the ability of the two TCR con-
structs to suppress the cell surface expression of the
endogenous TCR chains, we used murine splenocytes and
purified the T cells expressing Vβ8.1, 8.2 and 8.3 TCR,
which represented approximately 16% of the total T cells.
This allowed us to use antibodies specific for Vβ8.1,2,3 to
measure the expression of endogenous TCR, and antibod-
ies specific for the Vβ11 and Vβ5 chains to assess expres-
sion of the introduced F5-TCR and OTII-TCR, respective-
ly. Figure 1 shows the staining profile of purified Vβ8.1,2,3
T cells that were mock transduced, or transduced with the
retroviral constructs encoding the F5-TCR or the OTII-
TCR. The majority of freshly transduced T cells expressed
high levels of the introduced Vβ11 or Vβ5 TCR chains and
sharply reduced levels of the endogenous Vβ8.1,2,3
chains. Approximately 30% of the T cells expressed both
the introduced as well as the endogenous TCR chains.
Less than 10% of T cells expressed the endogenous TCR
only, which most likely represents untransduced T cells as
the efficiency of retroviral TCR gene transfer does not
usually reach 100%. We observed an inverse correlation
between the level of expression of the introduced TCR
and the expression levels of the endogenous TCR. For
example, the mean fluorescent intensity (MFI) of Vβ11 or
Vβ5 expression in the ‘single-positive’ T cells expressing
primarily the introduced TCR was higher than the Vβ11
or Vβ5 MFI in the ‘double-positive’ T cells expressing both
introduced as well as endogenous TCR. In the case of the
F5-TCR, the MFI for the introduced β chain in the ‘single’
versus ‘double-positive’ T cells was 16300 versus 11300,
and for the OTII-TCR the difference was 10300 versus
7815. Together, these experiments indicated that ‘domi-
nant’ TCR can suppress the cell surface expression of
endogenous TCR, and that the suppression was most
effective in T cells expressing high levels of the ‘dominant’
TCR.
Reduced toxicity of allo-reactive T cells expressing
‘dominant’ TCR
We used an MHC-mismatched bone marrow transplan-
tation model to test whether the introduction of the ‘dom-
inant’ F5-TCR into C57BL/6 T cells reduced the toxicity of
donor T-cell infusion into BALB/c mice transplanted with
C57BL/6 hematopoietic stem cells. BALB/c mice received
myeloablative irradiation and were then transplanted with
T-cell depleted C57BL/6 (Thy1.2) bone marrow, followed
by adoptive transfer of polyclonal donor T cells (Thy1.1)
that were mock transduced or transduced to express the
F5-TCR (Figure 2A).  A short course of high-dose IL2 was
given to promote in vivo T-cell expansion. 
Following transduction of the donor T cells, we used
flow cytometry sorting to purify cells expressing high lev-
els of the introduced Vβ11 chain (Figure 2B). These T cells
were adoptively transferred into the transplanted mice,
which were then monitored using weight loss and sur-
vival as two objectively measurable criteria of potential
toxicity caused by the infused T cells. After three weeks
the animals were sacrificed to analyze the number and the
phenotype of the engrafted T cells. Figure 2C shows that
the measured weight of mice treated with F5-TCR trans-
duced T cells was similar to the weight of control mice
receiving a bone marrow transplant, but no T cells. In con-
trast, mice treated with mock transduced donor T cells
showed substantial weight loss which was most pro-
nounced in the first week after T-cell transfer (Figure 2C).
Comparison of the weight score at day 8 showed that
A. Holler et al.
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Figure 1. TCR transfer suppresses expression of
endogenous TCR chains. BALB/c splenocytes
were Vβ8 sorted (representing one endogenous
TCR Vβ chain family) followed by mock transduc-
tion or transduction with the F5- or OTII-TCR and
then stained with antibodies against CD3, Vβ8
(endogenous TCR), Vβ11 (F5-TCR) or Vβ5 (OTII-
TCR) to assess the expression levels of endoge-
nous (endo) and introduced (intro) TCR. Plots
show live-gated CD3+ T cells. 
TCR transfer to suppress allo-reactivity
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Figure 2. Allogeneic T cells expressing introduced TCR display reduced toxicity in MHC-mismatched bone marrow transplantation (BMT) recipients. (A) Allogeneic
chimeras were generated by lethal irradiation of recipient BALB/c mice (Thy1.2) followed by reconstitution with T-cell depleted (TCD) C57BL/6 bone marrow (BM).
Mice received 3x106 C57BL/6 T cells (Thy1.1) transduced with the F5-TCR sorted to express high levels of the introduced Vβ11 chain. Control animals received 3x106
mock transduced C57BL/6 T cells (Thy1.1) or no T cells. To stimulate antigen driven expansion of F5-TCR donor T cells all mice were injected intraperitoneally with
0.5x106 C57BL/6 DCs loaded with NP peptide. 105U of IL2 were administered on the day of T-cell transfer and twice daily for the following two days. (B) Staining
profile of F5-TCR transduced T cells before and after Vβ11 sorting. The indicated P2 gate representing the top 33% of Vβ11-expressing T cells was used for FACS
sorting. Purity after sorting is shown. Plots show live-gated Thy1.1+ lymphocytes. (C) Kinetics of weight loss observed in the 3 groups of mice [(mock and F5-TCR
(Vβ11sorted) T cells: n=13; no T cells: n=12)]. Faint black lines represent individual mice and the bold black line represents the average of weight loss per group. Pooled
results of 3 independent experiments are shown. (D) Weight loss on day 8 and day 21 (end point). Symbols represent individual mice, bars show group averages. P
value for mock versus F5-TCR (Vβ11sorted) transduced T cells; P=0.0003 (weight loss on day 8: n=13 mice per group) and P=0.0057 [(weight loss on day 21, mock
transduced T cells: n=8; F5-TCR (Vβ11sorted) T cells: n=13)]. Pooled results of 3 independent experiments are shown. (E) Kaplan-Meier survival plot for mice receiving
mock or F5-TCR (Vβ11sorted) transduced T cells. P=0.015; n=13 mice per group. Pooled results of 3 independent experiments are shown. (F) Absolute number of trans-
ferred Thy1.1 donor T cells in the spleens of recipient mice. Symbols represent individual mice, bars show group averages (n=5 mice per group). One representative
experiment of 2 is shown. (G) Ex vivo phenotypical analysis of spleens. Splenocytes from mice that had received mock or F5-TCR (Vβ11sorted) transduced T cells were
stained with antibodies against Thy1.1, CD4, CD8, Vβ11 and NP-pentamer. Plots show live-gated Thy1.1+ T cells of one representative mouse per group. (H) Summary
of percentages of F5-TCR (Vβ11sorted) donor T cells binding Vβ11 antibody and NP-pentamer of all mice (n=3).
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mice treated with mock transduced donor T cells lost sig-
nificantly more weight than mice treated with F5-TCR
transduced T cells (Figure 2D). In fact, 5 out of 13 mice
succumbed to severe weight loss or had to be sacrificed in
accordance with UK Home Office regulations (Figure 2E).
The scoring of the surviving mice at week 3 after T-cell
transfer showed that the group treated with mock trans-
duced T cells continued to weigh significantly less than
the F5-TCR group (Figure 2D). Although these data indi-
cate that the F5-TCR prevented GvHD-associated weight
loss in the first three weeks, our experiments did not test
whether F5-TCR transduced T cells might cause long-term
pathology such as chronic GvHD. At week 3, all mice
were sacrificed to analyze the level of T-cell engraftment
and TCR expression. The absolute number of engrafted
donor Thy1.1 T cell in the spleen of recipient mice was
similar for mock and F5-TCR transduced T cells (Figure
2F). Flow cytometric analysis showed that the majority of
F5-TCR transduced T cells continued to express high lev-
els of the introduced Vβ11 chain. Surprisingly, staining
with H2-Db/NP-peptide pentamer reagents showed that
the majority of the Vβ11+ donor T cells were unable to
bind the pentamer, indicating that they did not express the
correctly paired F5-TCR α/β heterodimer, although they
expressed high levels of the F5-TCR β chain (Figure 2G
and H).
Pentamer-negative donor T cells expand preferentially
in vivo
We explored whether pentamer-negative T cells existed
before injection, or whether they arose in vivo from T cells
expressing F5-TCR α/β heterodimer. Most of the freshly
transduced T cells expressing high levels of the Vβ11 chain
did bind the pentamer, although a minority of T cells were
pentamer-negative (Figure 3A). If the pentamer-negative,
potentially allo-reactive T cells expanded preferentially
after in vivo transfer, then exclusion of these cells before
adoptive transfer should avoid the emergence of pen-
tamer-negative T cells. We therefore FACS purified trans-
duced donor T cells to obtain a highly pure Vβ11+/pen-
tamer+ population (Figure 3B). These C57BL/6 donor T
cells (Thy1.1) were then adoptively transferred into
A. Holler et al.
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Figure 3. Pentamer sorted T cells retain NP-pentamer binding in MHC-mismatched bone marrow transplantation (BMT) recipients. (A) The pre-injection Vβ11+ T-cell
population contains a small number of NP-pentamer negative cells. C57BL/6 splenocytes (depleted of the endogenous Vβ11 T-cell population) were transduced with
the F5-TCR and stained with antibodies against CD8 and Vβ11 (left panel). The right panel shows the NP-pentamer binding profile of the gated Vβ11+ T-cell popula-
tion. (B) FACS sorting of NP-pentamer binding T cells. C57BL/6 T cells were transduced with the F5-TCR and stained with antibodies against Vβ11 and NP-pentamer.
The P3 gate was used for FACS sorting. Purity after sorting is shown in the right panel. Plots show live-gated Thy1.1+ lymphocytes. (C) Ex vivo phenotypical analysis of
C57BL/6 donor T cells (Thy1.1) after adoptive transfer into BALB/c recipient mice previously transplanted with T-cell depleted C57BL/6 bone marrow. Donor T cells
were transduced with the F5-TCR and purified as shown in (B); mock transduced T cells were used as a control. Three weeks after T-cell transfer, mice were sacrificed
and splenocytes were stained with antibodies against Thy1.1, CD4, CD8, Vβ11 and NP-pentamer. Plots show Vβ11 staining (left panels) and NP-pentamer staining
(right panels) of live-gated Thy1.1+ donor T cells of mice that received mock transduced T cells or F5-TCR (NP-pentamersorted) T cells. 
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Figure 4. TCR transfer enhanced the anti-tumor effects of allogeneic T-cell therapy. (A) Allogeneic chimeras were generated by lethal irradiation of C57BL/6 mice
transplanted with allogeneic T-cell depleted bone marrow followed by EL4-NP tumor challenge and allogeneic T-cell therapy. The allogeneic bone marrow and T cells
were either of DBA/J1 origin (see Figure 4) or BALB/c origin (see Figure 5). (B) Tumor-bearing mice were treated with 1x106 F5-TCR-CD19 (NP-pentamersorted) bulk T
cells or purified CD8+ T cells from DBA/J1 donors. Control mice received no T cells or 1x106 GFP transduced and FACS sorted T cells from DBA/J1 donors. Tumor
growth observed in the 4 groups of mice is shown (n=5, except for the CD8+ group n=6). P values on day 11 post T-cell transfer are: GFP control T cells versus bulk
F5-TCR-CD19 T cells is non-significant (ns); bone marrow transplantation (BMT) control versus bulk F5-TCR-CD19 T cells (P=0.02) and GFP control T cells versus CD8+
F5-TCR-CD19 T cells (P=0.0002). (C) EL4-NP tumors from mice treated with F5-TCR-CD19 CD8+ T cells were re-isolated at the time point when mice were sacrificed
due to GvHD toxicity. They were cultured for four days and then mixed with F5-TCR transduced T cells to analyze IFNγ responses. Parental EL4-NP cells were used as
a positive control. FACS plots show percentage IFNγ production of transduced CD8+ T cells. (D) Kaplan-Meier survival plot for mice receiving GFP control T cells, F5-
TCR-CD19 bulk T cells or no T cells. (E) Clinical graft-versus-host disease (GvHD) severity score of mice treated with F5-TCR-CD19 CD8+ T cells. Mice were weighed
and assessed for signs of clinical GvHD 2-3 times a week (see Methods). GvHD score is shown. (F)  Ex vivo phenotypical analysis of mice treated with GFP control T
cells or F5-TCR-CD19 CD8+ T cells. Splenocytes were stained with antibodies against CD19, CD4, CD8, and NP-pentamer. Plots show the level of pentamer binding
of live-gated GFP+ T cells (left) and live-gated CD19+ T cells (right). Combined data of all analyzed mice are shown (G). Data of one representative mouse per group
are shown or combined data of all analyzed mice (F5-TCR n=6; GFP T cells n=1). 
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BALB/c recipients previously transplanted with C57BL/6
bone marrow cells (Thy1.2). As before, recipient mice
were sacrificed three weeks after T-cell transfer to deter-
mine TCR expression. The majority of Thy1.1 donor T
cells expressed high levels of Vβ11 and bound H2-Db/NP-
pentamer (Figure 3C). However, some of the re-isolated 
T cells did not bind pentamer ex vivo (Figure 3C). It is dif-
ficult to know whether these cells derived from the small
number (<1%) of pentamer-negative cells present prior to
transfer (Figure 3B) or whether they lost pentamer binding
in vivo.
TCR-transfer improves tumor protection of allogeneic
donor T-cell therapy 
We next explored whether transfer of the ‘dominant’ F5-
TCR enhanced the ability of donor T cells to control
tumor growth. To address this question, we challenged
C57BL/6 mice with syngeneic EL4 lymphoma cells
expressing the TCR-recognized NP antigen. Prior to tumor
challenge, the C57BL/6 mice (H2b) were transplanted with
T-cell depleted bone marrow from MHC-mismatched
BALB/c (H2d) or DBA/J1 (H2q) donor mice (Figure 4A).
While H2d mice express MHC class-II IE molecules, this is
not the case in H2b and H2q mice which lack the gene
encoding the alpha chain of the IE alpha/beta heterodimer.
Lack of IE molecules results in lack of the presentation of
endogenous super-antigens that are encoded by mouse
mammary tumor virus MTV8 and MTV9 present in the
genome of most inbred mouse strains.15 The presentation
of MTV8 and MTV9 by IE leads to the selective reduction
of T cells expressing the Vβ11 chain in the natural reper-
toire of BALB/c mice.16 Since the F5 TCR uses Vβ11, this is
expected to reduce T-cell engraftment in C57BL/6 mice
reconstituted with IE-positive BALB/c bone marrow,
while allowing efficient engraftment and persistence in
mice reconstituted with IE-negative DBA/J1 bone marrow. 
We first investigated allogeneic T-cell therapy of EL4-NP
tumor in C57BL/6 mice transplanted with DBA/J1 bone
marrow. DBA/J1 donor T cells were transduced with an
F5-TCR construct containing a CD19 marker 
(see Methods) to identify transduced T cells in vivo. As
control, donor T cells were transduced with GFP. We used
flow cytometry to sort donor T cells binding high levels of
NP-pentamer (F5-TCR) or for GFP expression (control)
prior to adoptive transfer. Compared to mice that did not
receive any T cells, the transfer of allogeneic GFP trans-
duced T cells did not reduce tumor growth (Figure 4B). In
contrast, treatment with allogeneic bulk T cells transduced
with the F5-TCR resulted in substantial reduction in
tumor burden. Transfer of purified TCR transduced CD8+
T cells was more effective than transfer of bulk T cells.
This is possibly due to our previous observation that CD8+
T cells expressing this TCR recognized approximately 10-
fold lower concentration of antigen than CD4+ T cells
expressing the same TCR.17 However, despite the near
elimination of tumors after treatment with DBA/J1 CD8+
T cells, protection was incomplete and tumors relapsed in
most animals. We explored whether this was due to
immune-editing and tumor escape. The analysis of tumors
re-isolated from the mice treated with TCR transduced
A. Holler et al.
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Figure 5. Depletion of TCR transduced T cells reduces toxicity and tumor protection. In these experiments, C57BL/6 mice were transplanted with BALB/c bone mar-
row and treated with TCR transduced BALB/c donor T cells (see Figure 4A). (A) EL4-NP tumor growth in mice receiving no T cells (n=3) or treated with mock (n=5) or
F5-TCR transduced bulk T cells (n=7). One representative experiment of 2 is shown. (B) Kaplan-Meier survival plot for mice receiving mock T cells (n=10), F5-TCR T
cells (n=11) or no T cells (n=8). Pooled data from 2 independent experiments are shown. (C) Absolute numbers of transferred mock or F5-TCR transduced T cells in
the spleen of treated mice, showing selective depletion of Vβ11+ F5-TCR T cells. 
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CD8+ T cells revealed that they no longer stimulated anti-
gen-specific cytokine production by responder T cells
expressing the F5-TCR (Figure 4C). This indicates that T-
cell therapy was effective, and that immune-edited escape
variants were responsible for tumor relapse in treated
mice.
The impressive anti-tumor activity of F5-TCR trans-
duced DBA/J1 T cells was also associated with improved
survival of F5-TCR treated mice. Mice that did not receive
any T cells or were treated with GFP control T cells died
between day 13-19 with progressive tumor growth (Figure
4D). In contrast, mice treated with F5-TCR transduced
CD8+ T cells did not die because of tumor growth, but
instead had to be sacrificed at day 26 because of develop-
ment of GvHD as assessed by clinical and histological
GvHD severity scoring (Figure 4E and Online
Supplementary Figure S1). When mice were sacrificed, we
used flow cytometry analysis of splenocytes to detect the
transferred DBA/J1 T cells by their expression of GFP (con-
trol T cells) or CD19 (TCR transduced T cells). Both, GFP+
and CD19+ T cells were readily detectable in the spleen of
treated mice. As expected, the gated GFP+ control T cells
did not bind the NP-pentamer, while most of the gated
CD19+ T cells were NP-pentamer-positive (Figure 4F).
However, the summary data of all mice show that 15%-
30% of the CD19+ T cells had lost pentamer staining, sug-
gesting that these T cells no longer expressed high levels
of the F5-TCR, but instead potentially allo-reactive
endogenous or mis-paired TCR that could account for the
observed GvHD toxicity (Figure 4G).
Finally, we explored whether the toxicity that was
observed approximately three weeks after T-cell transfer
could be reduced by limiting the in vivo persistence of the
F5-TCR transduced T cells. Therefore, we performed
tumor protection experiments in C57BL/6 mice reconsti-
tuted with BALB/c bone marrow. In these mice, treatment
with F5-TCR transduced BALB/c T cells delayed tumor
growth when compared to treatment with mock trans-
duced T cells (Figure 5A). The delay in tumor growth was
associated with improved survival of mice treated with
F5-TCR transduced BALB/c T cells (Figure 5B). In this set-
ting, the mice did not develop any signs of GvHD toxicity
but succumbed to progressive tumor growth. When mice
treated with control or F5-TCR T cells reached lethal
tumor burden, they were sacrificed and analyzed to deter-
mine the number of engrafted BALB/c T cells. As expect-
ed, control transduced T cells not bearing the F5-TCR
were readily detectable in the spleen of treated mice,
while the Vβ11-positive T cells expressing the F5-TCR
were selectively depleted (Figure 5C). The data indicated
that the depletion of the F5-TCR expressing T cells pre-
vented any detectable GvHD toxicity, but did not abolish
an improvement in tumor protection compared to mock
transduced T cells.
Discussion
Strategies to reduce graft-versus-host disease and
enhance anti-tumor activity of allogeneic T cells remain an
important area of research.18 Various approaches have
been developed, including the transfer of purified memory
T cells19,20 or the in vitro depletion of allo-reactive T cells
stimulated with recipient antigen-presenting cells.21-23
Similarly, in vitro stimulation of allo-reactive T cells in the
presence of co-stimulation blockade was used to induce 
T-cell anergy.24 An elegant alternative to the in vitro deple-
tion of allo-reactive T cells is the introduction of ‘suicide
genes’ that can be triggered in vivo in patients developing
GvHD after T-cell transfer.25-28 Most recently, the disrup-
tion of endogenous TCR genes has been achieved using
zinc finger nucleases, generating T cells unable to respond
to allo-stimulation in vitro.29,30 The introduction of TCR or
single chain antibody constructs has been used to equip
these TCR-disrupted T cells with new specificities.
In this study, we explored a simplified strategy to simul-
taneously suppress endogenous TCR expression while
introducing therapeutic TCR. The described approach is
based on the working hypothesis that ‘dominant’ TCR
can redirect T-cell specificity towards tumor antigens and
also suppress the expression of endogenous TCR that are
required for donor T cells to recognize major and minor
histocompatibility antigens involved in GvHD.
We have taken advantage of previous reports showing
that codon optimization and introduction of additional
cysteine bonds can improve TCR expression and reduce
unwanted mis-pairing.31-33 Using modified F5- and OTII-
TCR constructs, we found that both were effective in
suppressing the expression of endogenous TCR in the
majority of transduced primary T cells. We found that in
vitro selection of transduced T cells for high-level expres-
sion of introduced TCR β chain (using antibodies) or for
the correctly paired TCR α/β combination (using pen-
tamer) was required to reduce expression of potentially
allo-reactive endogenous TCR. Following in vivo transfer,
we observed the selective expansion of T cells that lost
pentamer binding, indicating that they expressed
endogenous or mis-paired TCR that might be driven by
alloantigen recognition in vivo. While pentamer selected
T cells remained largely pentamer-positive when they
were transferred into tumor-free mice, the transfer into
tumor-bearing recipients resulted in the accumulation of
pentamer-negative T cells. A major difference between
tumor-free and tumor-bearing mice is the absence and
presence, respectively, of the F5-TCR recognized target
antigen. It is possible that the stimulation via the F5-TCR
lowers the triggering threshold for endogenous or mis-
paired TCR that can recognize allo-antigens. Once trig-
gered, these allo-reactive T cells may preferentially
expand in the MHC-mismatched recipient mice. The
results described here are similar to the results obtained
by Koestner et al., when they showed that allogeneic T
cells engineered to express the OT1-TCR displayed
increased GvL and reduced GvHD activity.11 In these
studies, the engineered T cells contained some untrans-
duced cells and the OT1-TCR achieved only 20%-70%
reduction in the level of endogenous TCR expression. In
our case, we purified T cells for high expression of the
introduced F5-TCR, and this ‘dominant’ TCR was capa-
ble of suppressing endogenous TCR expression to unde-
tectable levels. Nevertheless, our results show that,
despite the use of purified T-cell populations, the in vivo
exposure to allo-antigens provided a strong selection for
reduced F5- and increased endogenous TCR expression.
When the F5-TCR transduced allogeneic T cells were
able to expand and persist in large numbers, they medi-
ated effective control of EL4 tumors expressing the TCR
recognized target antigen. Only immune-edited tumor
variants that were no longer recognized by the TCR
transduced T cells were able to grow progressively in
these mice. However, persistence of the TCR transduced
allogeneic T cells led to the delayed development of
severe GvHD toxicity, which was associated with the
enrichment of T cells that no longer expressed the F5-
TCR α/β combination. The GvHD toxicity was not seen
when the in vivo persistence of the F5-TCR transduced T
cells was limited. This was achieved by the use of recip-
ient mice presenting the Vβ11 depleting MTV8 and
MTV9 antigens in the context of MHC class-II IE mole-
cules. In this setting, the F5-TCR was still able to mediate
anti-tumor activity, but the lack of T-cell persistence was
associated with the lack of GvHD toxicity. These exper-
iments indicated that ‘dominant’ TCR gene transfer can
substantially enhance the anti-tumor activity of allogene-
ic T-cell therapy, but that long-term persistence of these
T cells leads to the expansion of allo-reactive T cells that
no longer express high levels of the ‘dominant’ TCR.
Although this relatively simple strategy of using ‘domi-
nant’ TCR can clearly improve tumor immunity, the
complete removal of the risk of GvHD requires the com-
plete depletion of endogenous TCR to avoid in vivo
expansion of allo-reactive specificities.29,30 
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